SYRS - Syndax appoints former Alnylam executive as new medical chief

The clinical-stage biotech, Syndax Pharmaceuticals (NASDAQ:SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer, effective immediately. She will replace Michael Meyers, who will remain with the company until June before taking up a consultancy role. The new “appointment is the result of a thorough succession planning process as we lay the groundwork for our evolution into a fully-integrated oncology company,” the R&D Head of Syndax, Briggs W. Morrison, noted. A former Senior Medical Director at Alnylam Pharmaceuticals, Dr. Madigan, has most recently served as Vice President, Head of Clinical Development at Syros Pharmaceuticals (NASDAQ:SYRS). In February, Syndax (SNDX) announced the appointment of the company’s Chief Operating Officer, Michael Metzger as its new Chief Executive.

For further details see:

Syndax appoints former Alnylam executive as new medical chief